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The treatment effects of the anti-androgen Enzalutamide
(ENZ) in patients with castration resistant prostate cancer
(CRPC) are short lived. Immunotherapy may improve
patient survival, however how efficacious these treatments
are for CRPC, particularly those that inhibit T cell check-
point molecules, remains questionable. Indeed, the lack of
PD-L1 expression on CRPC tumors has made rationalizing
the use of PD-1 blockade difficult for CRPC patients, how-
ever whether patients with ENZ resistant CRPC may be a
more relevant cohort to examine the efficacy of anti-PD1
therapies remains unknown. In this study, we show that
compared to CRPC, ENZ resistant CRPC expresses more
PD-L1 in vitro and expresses high levels of both PD-L1
and 2 in vivo, suggesting that up-regulation of immune
checkpoint molecules may be one unique mechanism of
ENZ resistance that is not observed in CRPC. Our results
also suggest that that ENZ resistant CRPC may not only be
able to suppress immune responses via intrinsic PD-L1
expression, but also through the induction of PDL-1 and 2
on innate immune subsets in the circulation. This hypoth-
esis was supported by our data showing an increased fre-
quency of PD-L1/2 expressing dendritic cells (DC) and
myeloid derived suppressor (MDSC) cells in the blood of
ENZ resistant tumor bearing mice compared to those with
CRPC. We also found that in vivo compared to CRPC,
ENZ resistant CRPC was able to prevent DC infiltration
into tumors and suppress DC activation, as marked by the
reduced frequency of CD80/86 and PD-L1/2 expressing
DC in the tumors. Moreover, we show for the first time
that CRPC patients progressing on ENZ treatment have
high frequencies of PD-L1+ DCs and PD-1+ CD8 T cells in
their blood. Taken together, our work suggests that ENZ
resistant CRPC in both mouse models and patients is asso-
ciated with strong expression of the targets for anti-PD1
therapy. These data provide impetus for future studies that
examine the relative contribution of tumor vs. immune cell
PD-L1 in the progression of CRPC to anti-androgen resis-
tance and the utility of monitoring circulating cell PD-L1
pathway activity in CRPC patients to predict responsive-
ness to checkpoint blockade immunotherapy.
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